Status:
ACTIVE_NOT_RECRUITING
Passive Safety Surveillance Data of Dengue Vaccine, Qdenga (TAK 003) in Private Vaccination Sites in Buenos Aires, Argentina.
Lead Sponsor:
Fundación Vacunar
Conditions:
Dengue Vaccines
Eligibility:
All Genders
4+ years
Brief Summary
The TAK-003 vaccine, Qdenga, developed by Takeda, was approved by ANMAT in April 2023 and has been available in Argentina since November 2023 for individuals from 4 years old and without limit of age....
Eligibility Criteria
Inclusion
- All individuals who were vaccinated with Qdenga at Vacunar centers since November 2023 still 1st November 2024, from 4 years of age with no upper limit in accordance with ANMAT approval and for whom safety data is available through the Vacunar centers passive surveillance systems.
Exclusion
- Reports with insufficient information to characterize the AEFI will be excluded from the analysis.
Key Trial Info
Start Date :
November 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2025
Estimated Enrollment :
112345 Patients enrolled
Trial Details
Trial ID
NCT06898775
Start Date
November 1 2023
End Date
June 1 2025
Last Update
March 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fundación Vacunar
Buenos Aires, Argentina